A longitudinal cohort study of urological complications predictable by pre-transplant lower urinary tract symptoms
Kidney transplant, lower urinary tract symptoms, urological complications
Patients will be recruited over two years and followed up until they are one year post-transplant, removed from the transplant waiting list or have died. All patients at the time of transplant and at the time of transplant wait-listing will be approached to offer participation. History, examination and all perioperative follow-up will be conducted as would be standard of care. Patients will be recruited in two phases: - PHASE 1 (enrolled at transplantation): Evaluation of patients beginning on the day of transplant, prospectively at 6 weeks and 1 year - PHASE 2 (enrolled at waitlisting): Evaluation of patients at time of waitlisting, prospectively 1-year post-waitlisting (if not yet transplanted), on day of transplant and at 6 weeks and 1-year post-transplant All patients will undergo baseline assessment with history, examination, questionnaires (IPSS for males and ICIQ-FLUTS for females), along with Uroflowmetry and post-void residual assessment. For patients who do not produce enough urine for conclusive results (≥130 ml), a small filling catheter will be used to instil saline, and repeat assessment will be conducted. This will be limited to 300ml, without pressure testing and does not constitute/imply invasive urodynamic testing. These assessments, along with review of medical notes, will be performed at the time of transplant listing (Phase 2), after 1 year on the transplant waiting list (Phase 1), on the day of transplant, 6 weeks and 12 months after transplantation.
Current key inclusion criteria as of 23/07/2026: 1. Adult patients (18 years of age or older) scheduled to undergo renal transplantation (both deceased and living donor candidates) 2. Able to give informed written consent to participate Previous key inclusion criteria: 1. Adult patients (18 years of age or older) scheduled to undergo first-time renal transplantation (both deceased and living donor candidates) 2. Able to give informed written consent to participate
1. Unable or unwilling to provide consent 2. Patients undergoing re-transplant 3. Patients undergoing simultaneous urological reconstructive procedures 4. Patients with previously reconstructed bladders (includes Augmentation cystoplasty, ileal conduit, neobladder etc.) 5. Significant cognitive impairment, which would limit their capacity to accurately report symptoms